Newsroom

LATEST PUBLICATIONS

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

wmm2023-04-10T20:24:04-07:00March 2nd, 2023|

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

wmm2022-12-29T21:22:21-08:00November 15th, 2022|

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

wmm2022-12-29T21:19:31-08:00June 4th, 2022|

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

wmm2023-01-08T18:20:36-08:00May 30th, 2022|

Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma

Invivoscribe Marketing2022-09-07T22:22:23-07:00May 3rd, 2022|

Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML

wmm2022-10-24T14:57:12-07:00October 24th, 2022|

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML

Invivoscribe Marketing2022-08-16T20:08:13-07:00August 16th, 2022|

Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine

wmm2022-05-09T17:27:05-07:00May 9th, 2022|

Roswell Park Comprehensive Cancer Center Licenses Invivoscribe’s LymphoTrack Software for Plug and Play Pipeline Use

Invivoscribe Marketing2021-09-02T16:53:40-07:00September 2nd, 2021|

Invivoscribe Announces Key Submission in the EU, Expanded Presence and Activity in China

Invivoscribe Marketing2021-07-22T17:27:56-07:00July 22nd, 2021|

JAMT

May 10-11, 2025
Osaka, Japan
Attending
Visit Conference Website

ASGCT

May 13-17, 2025
New Orleans, LA
Attending
Visit Conference Website

15th JSH International Symposium

May 16-17, 2025
Saga, Japan
Attending
Visit Conference Website

ASCO

May 30 – June 3, 2025
Chicago, IL
On-site Booth
Visit Conference Website

EHA

June 12-15, 2025
Milan, Italy
On-site Booth
Visit Conference Website

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

CE-IVD

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

CE-IVD

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Newsroom

Newsroom

LATEST PUBLICATIONS

LATEST PRESS

CONFERENCES

JAMT

ASGCT

15th JSH International Symposium

ASCO

EHA

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.